Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Earnings call suggestion

<< Previous

Bullboard Posts

Next >>

Comment by Spartrapon Feb 27, 2021 1:13pm

123 Views

Post# 32679235

RE:RE:RE:RE:RE:RE:RE:Earnings call suggestion

Sell side analysts' ratings have been a proven contrarian signal in biotech for some time now..
https://www.cnbc.com/2018/07/02/when-analysts-say-sell-a-biotech-stock-its-time-to-buy.html

scarlet1967 wrote: I know which makes it more difficult to understand, not engaged at all, didn't even bothered to ask questions yet he produced a report based on the PR. Time to bypass the analysts for now as it seems they only adjust their reports after the fact.

palinc2000 wrote: He wasn't even on the Call,,,,

scarlet1967 wrote: This is what happens when one is trying hard to work with incompetent analysts only.
Douglas W. Loe, at Leeds Jones downgraded the company to hold from speculative buy.